（文章来源：证券日报） 证券日报网讯 7月29日晚间，恩华药业发布公告称，2025年上半年实现归属于上市公司股东的净利润为 700，494，742.07元，同比增长11.38%。 ...

北京商报讯（记者 丁宁）7月29日晚间，恩华药业（002262）披露2025年半年度报告显示，报告期内， 公司实现营业收入30.1亿元，同比增长8.93%；归属净利润7亿元，同比增长11.38%。 报告期内，恩华药业主营业务为医药研发、生产和销售，医药销售含公司生产的原料和制剂销售以及医 药批发和零售业务。 ...

*ST海华（600243）公告：基于巴州鲁新鼎盛燃气有限公司（下称："鲁新鼎盛"）所处的天然气行业和 地理位置具有良好的发展前景，公司控股子公司茫崖源鑫拟与徐海波、徐瑶瑶、鲁新鼎盛签署《收购协 议》，约定控股子公司茫崖源鑫以现金4300万元取得鲁新鼎盛100%的股权。 神马电力：拟以3亿元—4亿元回购股份 药明康德：拟将回购股份价格上限调整为不超114.15元/股 *ST海华：控股子公司拟4300万元收购鲁新鼎盛100%股权 仕佳光子：上半年净利润2.17亿元，同比增长1712% 滨化股份：筹划发行H股股份并在香港联交所上市事项 恩华药业：上半年净利润7亿元，同比增11.38% 沪市重要公告： 药明康德：拟将回购股份价格上限调整为不超114.15元/股 药明康德（603259）公告：拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限由 不超过90.72元/股（含）调整为不超过114.15元/股，本次回购方案的其他内容不变。 *ST海华：控股子公司拟4300万元收购鲁新鼎盛100%股权 华勤技术：拟23.93亿元协议受让晶合集成6%股份 时空科技：实控人终止筹划控制权变更的重大事项，股票明起复 ...

恩华药业（SZ 002262，收盘价：22.93元）7月29日晚间发布半年度业绩报告称，2025年上半年营业收 入约30.1亿元，同比增加8.93%；归属于上市公司股东的净利润约7亿元，同比增加11.38%；基本每股收 益0.69元，同比增加11.29%。 （文章来源：每日经济新闻） ...

证券日报网讯 7月29日晚间，恩华药业发布公告称，公司第七届监事会第三次会议审议通过了《公司 2025年半年度报告全文及摘要》《关于2024年限制性股票激励计划授予的限制性股票第一个解除限售期 解除限售条件成就的议案》。 （编辑 任世碧） ...

（编辑 任世碧） 证券日报网讯 7月29日晚间，恩华药业发布公告称，公司第七届董事会第三次会议审议通过了《公司 2025年半年度报告全文及摘要》《关于2024年限制性股票激励计划授予的限制性股票第一个解除限售期 解除限售条件成就的议案》。 ...

Core Viewpoint - Enhua Pharmaceutical reported continuous growth in its operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] Financial Performance - The company achieved an operating revenue of 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - The net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase year-on-year [1] R&D Investment - Enhua Pharmaceutical invested approximately 395 million yuan in research and development, representing a 23.97% increase compared to the previous year [2] - The company has over 70 ongoing research projects in the pipeline and holds the largest product line in the central nervous system drug sector in China [2] Innovative Drug Development - The company has 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - Collaborations include partnerships with San Sheng Pharmaceutical and Harvard Medical School for various drug development projects [3] Digital Healthcare Development - Enhua Pharmaceutical has established a digital healthcare platform since 2015, which includes online consultation and health services, with over 70,000 registered doctors and more than 2 million patient visits annually [4] - The company has developed several digital mental health products, including AI-based psychological risk screening systems and virtual reality tools [4] Expansion and Partnerships - The company operates 25 psychological clinics and has signed contracts with over 400 corporate clients, covering nearly 2 million individuals [5] - Enhua Pharmaceutical is actively pursuing overseas listing plans to expand financing channels and support business growth [5]

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, an increase of 11.38% year-on-year [1] - The basic earnings per share stood at 0.69 yuan [1] R&D Investment and Projects - The company has over 70 ongoing research projects with a research expenditure of 395 million yuan, reflecting a growth of 23.97% compared to the same period last year [2] - In the area of innovative drug development, there are currently 17 ongoing projects, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II trials [2] - The company is also engaged in 48 generic drug projects, with 1 project having received production approval and 5 projects currently under review for production [2]

Financial Performance - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, showing a year-on-year growth of 11.38% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 699 million yuan, with a year-on-year increase of 10.33% [1] - The basic earnings per share were 0.69 yuan [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of 395 million yuan, which is a 23.97% increase compared to the same period last year [2] - In the field of innovative drug development, there are currently 17 innovative drug projects under research, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II clinical trials [2] - The company is conducting 48 projects in generic drug development, with 1 project having received production approval and 5 projects currently under review for production approval [2]